Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage (FLUOCOL-1)

Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage: a Single-blind Phase III Multicenter Randomized Controlled Trial (Intergroup FRENCH-GRECCAR Trial)

Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the world and the third in France. Its incidence is steadily rising in developing nations. Anastomotic leak (AL) is a major problem in colorectal surgery affecting at least 7% of patients operated on for left colonic cancer. It is the most feared complication after colorectal anastomosis, associated with mortality, prolonged hospitalization, impaired health related quality of life (HRQoL) and increased health care costs. Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG) may help preventing AL. Available studies on the effects of IOFA with ICG are heterogeneous and randomized controlled trial are scarce. Our aim is to demonstrate that IOFA with ICG could lead to a reduction of AL rate after left-sided or low anterior resection with anastomosis for CRC.

The FLUOCOL-1 study is the first national, multicenter, single blind, randomized, 2-arm, phase III superiority clinical trial. The primary endpoint is the occurrence of an AL 90 days post-operation. AL is defined as any anastomotic dehiscence with leakage into the pelvic cavity diagnosed upon imaging or at surgical exploration or any isolated pelvic organ-space infection with no evidence of fistula as defined by the International Study Group of Rectal Cancer.

The study population will be made of adult patients with left-sided or high rectal cancer scheduled to undergo elective left colectomy or high rectal resection (by open, laparoscopy or robotic surgery) and with expected stapled or hand-sewn intraperitoneal anastomosis. The exclusion criteria are mainly an emergent surgery; rectal cancer requiring total mesorectal excision and anastomosis expected below the peritoneal reflection; CRC requiring total or subtotal colectomy; CRC requiring transverse colectomy; recurrent CRC and locally advanced colorectal cancer requiring multi-visceral excision.

A total of 1010 patients will be necessary (39 patients in each centre during 36 months). An interim analysis for efficacy and futility is scheduled when half of the participants will have been recruited.

In case of positive results favoring IOFA, this study would define the use of IOFA as a standard of care in colorectal surgery. At the patient level, a significantly lower rate of AL will reduce hospital stay and stoma rate, and will ensure improved postoperative recovery, faster return to normal activity and better long-term oncologic outcomes.

Study Overview

• Status: Recruiting
• Conditions: Colorectal Cancer
• Intervention / Treatment: Drug: FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).

Detailed Description

Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the world and the third in France. Its incidence is steadily rising in developing nations. Anastomotic leak (AL) is a major problem in colorectal surgery affecting at least 7% of patients operated on for left colonic cancer. It is the most feared complication after colorectal anastomosis, associated with mortality, prolonged hospitalization, impaired health related quality of life (HRQoL) and increased health care costs. Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG) may help preventing AL. Available studies on the effects of IOFA with ICG are heterogeneous and randomized controlled trial are scarce. Our aim is to demonstrate that IOFA with ICG could lead to a reduction of AL rate after left-sided or low anterior resection with anastomosis for CRC.

The FLUOCOL-1 study is the first national, multicenter, single blind, randomized, 2-arm, phase III superiority clinical trial. The primary endpoint is the occurrence of an AL 90 days post-operation. AL is defined as any anastomotic dehiscence with leakage into the pelvic cavity diagnosed upon imaging or at surgical exploration or any isolated pelvic organ-space infection with no evidence of fistula as defined by the International Study Group of Rectal Cancer.

The study population will be made of adult patients with left-sided or high rectal cancer scheduled to undergo elective left colectomy or high rectal resection (by open, laparoscopy or robotic surgery) and with expected stapled or handsewn intraperitoneal anastomosis. The exclusion criteria are mainly an emergent surgery; rectal cancer requiring total mesorectal excision and anastomosis expected below the peritoneal reflection; CRC requiring total or subtotal colectomy; CRC requiring transverse colectomy; recurrent CRC and locally advanced colorectal cancer requiring multi-visceral excision.

The 26 participating centres are equipped with a scope with near-infrared (NIR) light source allowing real-time ICG perfusion assessment. The co-investigators are experienced digestive surgeons trained to work with and without IOFA. They have considerable experience in working together on research projects and have a proven track-record of efficacy. Moreover, this study will receive valuable support from the Surgery Research Network (FRENCH) and the Surgical Research on Rectal Cancer Group (GRECCAR), which have proved their ability to recruit patients into various multicentric studies and with which the FLUOCOL-1 project has been discussed.

The duration of participation for each patient is 90 days. The 3 study visits are superimposed to the schedule of standard of care (V1: pre-operation visit of selection and inclusion; Surgery; V2: 30-day post-operation visit and V3: 90-day post-operation visit).

The surgeon will do the 1:1 randomization between V1 and the day before surgery (D-30 to D-1). To reduce the risk of bias, patients will be blinded to the study group and the randomization will be stratified on participating centres, Body Mass Index (BMI), physical status classification score (=ASA score), preoperative treatment and tumor location. Patient will be assigned in the intervention (IOFA) or the control group (no IOFA).

At the exception of the information given on the study to the patient, the gathering of the written consent, the randomization and the HRQoL questionnaires, the patient will be treated following standard of care. Study data are the data systematically collected in the patient medical file except for the HRQoL questionnaires that will be collected under the supervision of a research technician financed by the study. The technician will capture the study data and the de-identified pdf version of the medical reports (consultations and hospitalizations) in the electronic Case Report Form (eCRF) after every visit.

A total of 1010 patients will be necessary (39 patients in each centre during 36 months). An interim analysis for efficacy and futility is scheduled when half of the participants will have been recruited.

The ICG will be graciously provided by the manufacturer (SERB). An investigator meeting will be organized twice a year during the annual GRECCAR and FRENCH meetings. Newsletters will be sent every 3 months.

In case of positive results favoring IOFA, this study would define the use of IOFA as a standard of care in colorectal surgery. At the patient level, a significantly lower rate of AL will reduce hospital stay and stoma rate, and will ensure improved postoperative recovery, faster return to normal activity and better long-term oncologic outcomes.

• Study Type: Interventional
• Enrollment (Estimated): 1010
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Zaher Lakkis, MD, PhD; Phone Number: +33.3.81.66.83.41; Email: zlakkis@chu-besancon.fr
• Study Contact Backup: Name: Jean-Baptiste Pretalli, PhD; Phone Number: +33.3.81.21.81.27; Email: jbpretalli@chu-besancon.fr

Study Locations

• France
  • Amiens, France, 80054
    • Recruiting
    • Centre Hospitalier Universitaire Amiens-Picardie
    • Contact: Jean-Marc REGIMBEAU; Email: regimbeau.jean-marc@chu-amiens.fr
  • Annecy, France
    • Recruiting
    • CH Annecy
    • Contact: Olivier OULIE, MD
  • Besançon, France, 25000
    • Recruiting
    • Centre Hospitalier Universitaire de Besançon
    • Contact: Zaher LAKKIS; Email: zlakkis@chu-besancon.fr
  • Bourgoin-Jallieu, France, 38302
    • Recruiting
    • Centre Hospitalier Bourgoin-Jallieu
    • Contact: Pierre Goubault; Email: pierre.goubault@ghnd.fr
  • Dijon, France
    • Recruiting
    • Centre Georges Francois Leclerc
    • Contact: David ORRY
  • Dijon, France, 21000
    • Recruiting
    • University Hospital of Dijon
    • Contact: Nathan Moreno; Email: nathan.moreno@chu-dijon.fr
  • La Tronche, France, 38700
    • Recruiting
    • Centre Hospitalier Universitaire de Grenoble
    • Contact: Bertrand TRILLING; Email: btrilling@chu-grenoble.fr
  • Lille, France, 59037
    • Recruiting
    • Centre Hospitalier Universitaire de Lille
    • Contact: Guillaume Piessen; Email: guillaume.piessen@chrulille.fr
  • Lyon, France, 69310
    • Recruiting
    • Centre Hospitalier Lyon-Sud
    • Contact: Eddy Cotte; Email: eddy.cotte@chu-lyon.fr
  • Lyon, France, 69009
    • Recruiting
    • Centre Lyonnais de Chirurgie Digestive
    • Contact: Benoit Gignoux; Email: gignoux@chirurgiendigestif.com
  • Marseille, France, 13009
    • Not yet recruiting
    • Institut Paoli Calmettes
    • Contact: Cécile DE CHAISEMARTIN; Email: dechaisemartinc@ipc.unicancer.fr
  • Marseille, France, 13005
    • Recruiting
    • Hôpital La Timone
    • Contact: Diane MEGE; Email: dr.dianemege@gmail.com
  • Marseille, France, 13015
    • Recruiting
    • Hopital Nord AP-HM
    • Contact: Laura BEYER-BERJOT; Email: laura.beyer@ap-hm.fr
  • Marseille, France, 13003
    • Recruiting
    • Hôpiatl Européen
    • Contact: Régis Fara; Email: r.fara@hopital-europeen.fr
  • Marseille, France
    • Recruiting
    • Hôpital St Joseph Marseille
    • Contact: Caroline ROSSI; Email: rossicaroline.k@gmail.com
  • Nancy, France
    • Recruiting
    • Chu de Nancy
    • Contact: Frédéric MARCHAL, MD PhD; Email: f.marchal@nancy.unicancer.fr
  • Paris, France, 75010
    • Recruiting
    • Hopital Saint Louis
    • Contact: Leon Maggiori; Email: lmaggiori@gmail.com
  • Paris, France, 75014
    • Recruiting
    • Hôpital Cochin
    • Contact: Mahaut LECONTE; Email: Mahaut.Leconte@aphp.fr
  • Paris, France
    • Recruiting
    • Hôpital Européen Georges Pompidou
    • Contact: Gilles MANCEAU, MD; Email: gilles.manceau@aphp.fr
  • Paris, France, 75012
    • Recruiting
    • Hôpital Saint Antoine
    • Contact: Jérémie LEFEVRE; Email: jeremie.lefevre@aphp.fr
  • Paris, France, 94275
    • Recruiting
    • Hopital Bicetre
    • Contact: Stéphane BENOIST, MD; Email: stephane.benoist@aphp.fr
  • Pontoise, France, 95300
    • Recruiting
    • Centre Hospitalier de Pontoise
    • Contact: Nelson Trelles; Email: nelson.trelles@ght-novo.fr
  • Reims, France, 51100
    • Recruiting
    • Hopital Robert Debre
    • Contact: Cyril Perrenot; Email: perrenotcyril@gmail.com
  • Rennes, France
    • Recruiting
    • CH Pontchaillou
    • Contact: Veronique DESFOURNEAUX-DENIS, MD
  • Rouen, France, 76000
    • Recruiting
    • Centre Hospitalier Universitaire de Rouen
    • Contact: Jean-Jacques TUECH; Email: jean-jacques.tuech@chu-rouen.fr
  • Saint-Herblain, France, 44800
    • Recruiting
    • Santé Atlantique
    • Contact: Antoine Sina; Email: antoine.sina@hotmail.fr
  • Strasbourg, France, 67000
    • Not yet recruiting
    • Centre Hospitalier Universitaire de Strasbourg
    • Contact: Benoît ROMAIN; Email: benoit.romain@chru-strasbourg.fr
  • Toulouse, France, 31400
    • Recruiting
    • CHU de TOULOUSE
    • Contact: Etienne BUSCAIL, MD; Email: ebuscail@me.com
  • Toulouse, France
    • Recruiting
    • Clinique Tivoli
    • Contact: Quentin DENOST, MD PhD
  • Tours, France, 37170
    • Recruiting
    • Centre Hospitalier de Tours
    • Contact: Medhi Ouaissi; Email: m.ouaissi@ch.tours.fr
  • Villejuif, France, 94805
    • Recruiting
    • Gustave Roussy
    • Contact: Leonor Benhaim; Email: leonorbenhaim@gustaveroussy.fr
  • vandoeuvre les Nancy, France
    • Recruiting
    • Institut Cancérologie de Lorraine
    • Contact: Cécilia CERIBELLI, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult patients (age >18 years)
• Scheduled to undergo elective left colectomy or high rectal resection for cancer with intraperitoneal anastomosis.
• Signed consent
• Affiliated to the French social security system (CMU included).

Exclusion Criteria:

• Emergent surgery.
• Rectal cancer requiring total mesorectal excision and anastomosis below the peritoneal reflexion.
• Colon cancer requiring total or subtotal colectomy defined as a right colectomy extended to the splenic flexure or more).
• Colon cancer requiring transverse colectomy.
• Recurrent colorectal cancer.
• Locally advanced colorectal cancer requiring multi-visceral excision.
• History of colectomy.
• Associated concomitant resection of other organ (liver, etc.).
• Previous pelvic radiotherapy for pathology unrelated to diagnosis with colon cancer e.g. treatment for prostate cancer.
• Inflammatory bowel disease.
• History of known allergy to indocyanine.
• Pregnant patients.
• Refusal to participate or inability to provide informed consent.
• Protected adults (individuals under guardianship by court order).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FLUO+; Experimental arm = surgery with IOFA. In the experimental arm, cancer resection and anastomosis will be performed after assessment of descending colon perfusion using intravenous injection of indocyanine green 0.1ml/kg.	Drug: FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).; In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist. The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera. A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits. An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded.
No Intervention: FLUO-; Control arm = Surgery without IOFA. In the control arm, cancer resection and anastomosis will be performed without intraoperative fluorescence angiography.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anastomotic leakage 90 days after surgery	The primary outcome is the occurence of an anastomotic leakage during the 90 days following surgery. Anastomotic leakage is defined as any clinical signs of leakage diagnosed by radiological examination or surgical exploration, or as any isolated pelvic organ infection without leakage evidence, as defined by the International Rectal Cancer Study Group.	90 days after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in planned anastomotic site.	Change in planned anastomosis during surgery is defined as any decision change on perfusion assessment such as modifying the initially planned transection level of the descending colon or refashioning anastomosis including the decision to undertake a permanent stoma rather than an anastomosis.	During surgery
Rate of patients with a defunctioning stoma.	The rate of defunctioning stoma created in the initial surgery as a temporary diverting pathway will be calculated.	Surgery time.
Overall 30-day postoperative morbidity.	Overall 30-day postoperative morbidity is defined and classified according to the Clavien-Dindo classification.	30 days after surgery.
Overall 90-day postoperative morbidity.	Overall 90-day postoperative morbidity is defined and classified according to the Clavien-Dindo classification.	90 days after surgery.
Mortality rate.	90-day postoperative mortality.	90 days after surgery.
Hospital length of stay.	Postoperative length of hospital stay.	End of hospital stay.
Postoperative reintervention.	Postoperative reintervention number and type within 90 days.	90 days after surgery.
Quality of life assessment.	Health related quality of life is assessed using the quality of life questionnaires : QLQ-C30 and QLQ-CR29 at baseline and 90 days post-operation. The QLQ-C30 is a patient self-rating questionnaire (30 questions) that measures physical, role, social, emotional, and cognitive functions as well as overall QoL. Scores can be linearly transformed to provide a score from 0 to 100 REF. Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales. The QLQ-CR29 (Quality of life of rectal cancer patients with 29 questions) has five functional and 18 symptom scales. It contains four subscales (urinary frequency (UF), blood and mucus in stool (BMS), stool frequency (SF), and body image (BI)) and 19 single items. The score can range from 0 to 100. Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales.	90 days after surgery.
Medico-economic analysis	The medico-economic analysis takes into consideration health care costs up until 90 days post-operation.	90 days after surgery.

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Besancon

Publications and helpful links

General Publications

• Wojcik M, Doussot A, Manfredelli S, Duclos C, Paquette B, Turco C, Heyd B, Lakkis Z. Intra-operative fluorescence angiography is reproducible and reduces the rate of anastomotic leak after colorectal resection for cancer: a prospective case-matched study. Colorectal Dis. 2020 Oct;22(10):1263-1270. doi: 10.1111/codi.15076. Epub 2020 May 18.

Study record dates

Study Major Dates

• Study Start (Actual): September 26, 2022
• Primary Completion (Estimated): October 31, 2025
• Study Completion (Estimated): October 31, 2025

Study Registration Dates

• First Submitted: December 9, 2021
• First Submitted That Met QC Criteria: December 9, 2021
• First Posted (Actual): December 23, 2021

Study Record Updates

• Last Update Posted (Actual): February 16, 2024
• Last Update Submitted That Met QC Criteria: February 15, 2024
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Colorectal surgery; Prevention; Anastomotic leakage; Indocyanine green; fluorescence angiography; Colic surgery; Complication; Rectal surgery
• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Anastomotic Leak
• Other Study ID Numbers: 2021-582

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No